Compare CPK & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPK | VKTX |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.3B |
| IPO Year | 1995 | 2014 |
| Metric | CPK | VKTX |
|---|---|---|
| Price | $124.30 | $28.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $142.00 | $95.86 |
| AVG Volume (30 Days) | 109.4K | ★ 1.7M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 13.50 | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $930,000,000.00 | N/A |
| Revenue This Year | $8.39 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $49.11 | ★ N/A |
| Revenue Growth | ★ 18.14 | N/A |
| 52 Week Low | $117.64 | $22.96 |
| 52 Week High | $140.59 | $43.15 |
| Indicator | CPK | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 36.64 |
| Support Level | $123.28 | $25.77 |
| Resistance Level | $128.81 | $36.77 |
| Average True Range (ATR) | 2.66 | 1.25 |
| MACD | -0.31 | -0.14 |
| Stochastic Oscillator | 49.19 | 0.19 |
Chesapeake Utilities Corp is an energy delivery company engaged in the distribution of natural gas, electricity, and propane; the transmission of natural gas; the generation of electricity and steam; and providing mobile compressed natural gas and other energy-related services to its customers. The company operates in two reportable segments, Regulated Energy and Unregulated Energy. The company's natural gas and electric distribution operations in Delaware, Maryland, and Florida are subject to regulation by PSC. Eastern Shore's natural gas transmission is subject to regulation by the FERC, and Peninsula Pipeline and Aspire Energy Express, its intrastate pipeline subsidiaries, are subject to regulation by the Florida PSC and Public Utilities Commission of Ohio, respectively.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.